Speaker Profile
Ph.D., Professor of Neurosurgery and Molecular & Medical Pharmacology, UCLA School of Medicine
Biography
Dr. Prins’s is a member of the Parker Institute for Cancer Immunotherapy, the Jonsson Comprehensive Cancer Center, and Basic Science PI of the UCLA SPORE in Brain Cancer. Dr. Prins is a tumor immunologist with more than 20 years of experience in brain tumor immunotherapy, pre-clinical models, and clinical trials of malignant glioma patients. His research group studies immune-based therapies for the treatment of central nervous system (CNS) tumors. Currently, patients presenting with such malignancies are left with few treatment options. His research group is attempting to apply what we learn from pre-clinical models towards the implementation of immunotherapy clinical trials for brain tumor patients. Their work is currently involved in the following pre-clinical and clinical studies.
Session Abstract – PMWC 2020 Silicon Valley
Session Synopsis: The advent of immunotherapy has revolutionized cancer treatment. Specifically, the development of antibodies that target and block signaling through immune checkpoints has led to promising clinical results in a variety of cancers. Antibodies against immune checkpoints such as CTLA-4, PD-1, and PD-L1 have received FDA approval for the treatment of a growing number of solid tumors. Despite the success of single-agent immune checkpoint blockade therapy, clinical benefit has been limited to a minority of patients. This session will explore emerging checkpoint inhibitors and other immunomodulatory agents designed to further improve clinical response rates and outcomes.
